Data integrity programs in pharmaceutical organizations typically focus on what people do with data: how forms are completed, how records are approved, how audit trails are maintained in validated systems. These are the right things to focus on. But they miss a significant and often overlooked source of risk: what lab instruments do with data automatically, and where that data goes after the instrument generates it.
Lab instruments, chromatography systems, spectrophotometers, balances, dissolution testers, generate output files continuously during normal operation. These files contain the raw data that underlies testing decisions, batch release determinations, and stability conclusions. They are the most critical GxP data in the organization. And in most pharmaceutical facilities, they sit in uncontrolled network folders with no access restrictions, no audit trail, and no version management.
| FDA inspectors examining data integrity findings frequently focus not on the summary reports submitted but on the raw data files that generated those reports. The gap between what is in the controlled system and what is in the instrument folder is often where integrity failures are found. |
Where lab data integrity failures actually happen
A chromatography workstation generates a raw data file every time an analysis is run. That file is typically saved to a network folder accessible to everyone in the lab. It can be opened, modified, and re-saved without any record of the change. If a peak is reintegrated to achieve a different result, the original integration may be overwritten with no trace.
| FDA 483 OBSERVATION PATTERN |
|---|
| A recurring pattern in FDA inspection observations is the finding that 'laboratory data was not adequately controlled to prevent unauthorized access or alteration' and that 'the firm could not demonstrate that raw data files generated by laboratory instruments were retained in their original form.' These findings appear across the industry, at organizations of all sizes. |
FDA's 2018 Data Integrity guidance requires that original raw data be retained in a form that allows it to be compared against the reported result. If the raw data file has been modified, overwritten, or is simply missing, the firm cannot demonstrate that the reported result reflects the actual original measurement.
Why lab instruments are a special compliance problem
Lab instruments were not designed for 21 CFR Part 11 compliance. The Part 11 requirements for audit trails, access controls, and electronic signatures were developed for computer systems, which describes what a lab instrument does, but the instruments themselves rarely implement these controls natively.
The version management problem
When a lab analyst reruns a sample, two raw data files exist: the original run and the rerun. Both should be retained. The relationship between them needs to be documented. In an uncontrolled environment, the analyst may overwrite the original file with the rerun, or have no system for relating the two files to each other. Both are data integrity findings.
The AI opportunity specific to lab data
Once instrument files are continuously monitored, version-controlled, and stored with full access tracking, they become the input for AI anomaly detection on raw instrument data. An AI system monitoring instrument output files over time can detect integration parameter changes that systematically shift results, file modification timestamps that do not align with the analysis schedule, repeated deletions and recaptures of the same analysis, and access patterns inconsistent with normal analyst behavior. None of these signals are detectable without a controlled instrument data environment.
How CIMCON's LabMonitor solves the lab instrument compliance gap
CIMCON's LabMonitor was developed specifically for and in close collaboration with the life sciences industry to address the gap between what instruments generate and what validated systems control. It provides continuous, automatic monitoring of lab instrument output folders without requiring any action from the analyst.
| CIMCON LabMonitor part11solutions.com/lab-management/ |
|---|
Continuous, automatic monitoring of lab instrument folders, turning uncontrolled raw data files into ALCOA+-compliant, AI-ready records.
|
The AI payoff from LabMonitor is direct and immediate: once instrument files are continuously monitored and version-controlled, they become a structured, traceable data asset that AI systems can analyze. The same infrastructure that satisfies FDA's requirement to retain raw data in its original form also creates the controlled data environment required to use that data in GxP AI applications.
| Continuous monitoring of lab instrument data is both a compliance requirement and a foundation for AI-enabled quality oversight. The two are not separate investments, they are the same investment, with returns on both dimensions. |
The bottom line
Lab instrument data is not an afterthought in pharmaceutical data integrity, it is the foundation. The raw data files generated by lab instruments are the most direct record of what was actually measured, and they are the records FDA inspectors examine when they suspect data integrity failures.
LabMonitor addresses this gap directly: continuous monitoring, version control, access controls, and a full audit trail, deployed as an overlay on existing lab infrastructure with no change to how analysts work.
| The question is not whether to control lab instrument data. The regulatory requirement has been in place since 2018. The question is whether the control environment in place actually meets that requirement, and for most organizations, an honest assessment reveals that it does not. |